Trial site
University of Maryland Greenebaum Comprehensive Cancer Center
- 27running trials
- 3closed trials
The trials here
What the 31 trials at this site are about, from their registry records.
- Conditions
- Lung cancer10 trials
- Diffuse large B-cell lymphoma4 trials
- Multiple myeloma4 trials
- Acute myeloid leukaemia2 trials
- Childhood cancers2 trials
- Head and neck cancer2 trials
- Prostate cancer2 trials
- Acute lymphoblastic leukaemia1 trial
- Chronic lymphocytic leukaemia1 trial
- Follicular lymphoma1 trial
- Kidney cancer1 trial
- Mantle cell lymphoma1 trial
- and 3 more
- Phase
- Phase 210 trials
- Phase 18 trials
- Phase 38 trials
- Phase 1/22 trials
- Phase 2/32 trials
- Status
- Active, not recruiting15 trials
- Recruiting11 trials
- Terminated2 trials
- Completed1 trial
- Enrolling by invitation1 trial
- Suspended1 trial
- Lead sponsor
- Kite, A Gilead Company4 trials
- University of Maryland, Baltimore3 trials
- Alliance Foundation Trials, LLC.2 trials
- Poseida Therapeutics, Inc.2 trials
- Regeneron Pharmaceuticals2 trials
- and 18 more
Running trials
Recruiting
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial
Recruiting
Recruiting
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Active, not recruiting
Active, not recruiting
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Recruiting
Recruiting
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Recruiting
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
Active, not recruiting
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Active, not recruiting
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Recruiting
Enrolling by invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
Active, not recruiting
Active, not recruiting
Active, not recruiting
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Active, not recruiting
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Active, not recruiting
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Active, not recruiting
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer6 recruiting
- Childhood cancers2 recruiting
- Diffuse large B-cell lymphoma2 recruiting
- Prostate cancer2 recruiting
- Mesothelioma1 recruiting
- Triple-negative breast cancer1 recruiting
Closed trials
Terminated
Completed
Terminated
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Site data: ClinicalTrials.govUpdated 17 Nov 2026